ArticleEpilepsy currents2011
Revisiting AMPA receptors as an antiepileptic drug target.
Article in Epilepsy currents, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 315 citations in OpenAlex.
- Perampanel add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2023Pooled it
- Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality.Epilepsia · 2021Pooled it
- Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy.CNS drugs · 2013Pooled it
- Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.Neurology · 2012Trial
- Narrative Review: Efficacy, Safety, and Tolerability of Newer Third-Generation Antiseizure Medications for Focal Epilepsy: A New Benchmark in Treatment Outcomes?Neurology and therapy · 2026Review
- Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer.International journal of molecular sciences · 2026Article
- Review
- Article
- Exploration of Canarium odontophyllum fruit phytoconstituents as potential candidates against epilepsy using in silico studies.Journal, genetic engineering & biotechnology · 2025Article
- USP47 Regulates Excitatory Synaptic Plasticity and Modulates Seizures in Murine Models by Blocking Ubiquitinated AMPAR Degradation.Neuroscience bulletin · 2025Article
- Anticonvulsant Potential of 1-Aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines: Insights from Strychnine and Nicotine Models in In Vivo and In Silico Studies.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cortical Excitability Before and After Long-Term Perampanel Treatment for Epilepsy.Annals of clinical and translational neurology · 2025Article
- Usefulness of perampanel as initial monotherapy in children with non-lesional focal epilepsy.Epilepsy & behavior reports · 2025Article
- Inhibition of NMDA receptors and other ion channel types by membrane-associated drugs.Frontiers in pharmacology · 2025Review
- Bioengineering strategy to promote CNS nerve growth and regeneration via chronic glutamate signaling.Acta biomaterialia · 2024Article
- Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials.EClinicalMedicine · 2024Article
- Efficacy and safety of modified medium-chain triglyceride ketogenic diet in patients with drug-resistant epilepsy.Acta epileptologica · 2024Article
- Targeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment.Science advances · 2024Article
- Therapeutic drug monitoring of perampanel: Clinical utility and impact of co-medication on pharmacokinetic variability.Heliyon · 2024Article
- Caring for Individuals with Alzheimer's Disease: A Spotlight on Hispanic Caregivers.Journal of Alzheimer's disease reports · 2024Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the 1990s there was intense interest in ionotropic glutamate receptors as therapeutic targets for diverse neurological disorders, including epilepsy. NMDA receptors were thought to play a key role in the generation of seizures, leading to clinical studies of NMDA receptor blocking drugs in epilepsy. Disappointing results dampened enthusiasm for ionotropic glutamate receptors as a therapeutic target. Eventually it became appreciated that another type of ionotropic glutamate receptor, the AMPA receptor, is actually the predominant mediator of excitatory neurotransmission in the central nervous system and moreover that AMPA receptors are critical to the generation and spread of epileptic activity. As drugs became available that selectively target AMPA receptors, it was possible to demonstrate that AMPA receptor antagonists have powerful antiseizure activity in in vitro and in vivo models. A decade later, promising clinical studies with AMPA receptor antagonists, including the potent noncompetitive antagonist perampanel, are once again focusing attention on AMPA receptors as a drug target for epilepsy therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.